RLMD - Relmada's REL-1017 indicates lack of abuse potential in late-stage major depressive disorder study

Relmada Therapeutics (RLMD) announces top-line results of the human abuse potential ((HAP)) study with REL-1017, the company's lead candidate in Phase 3 development for the treatment major depressive disorder ((MDD)).Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg and 150 mg) tested in recreational opioid users, demonstrated a highly statistically significant difference vs. the active control drug, oxycodone 40 mg.The study's primary endpoint was a measure of "likability" with the subjects rating the maximum effect (or Emax) for Drug Liking "at the moment", using a 1=100 bipolar rating scale (known as a visual analog scale or VAS).Mean Emax for Drug Liking for REL-1017 at 25, 75 and 150 mg dose 53.0, 58.2, 64.9, respectively compared to 51.7 for placebo and 85.0 for Oxycodone 40 mg."These results, along with previously published literature, confirm the lack of opioid effects of REL-1017. We look forward to the continued clinical development of

For further details see:

Relmada's REL-1017 indicates lack of abuse potential in late-stage major depressive disorder study